Crinetics (CRNX) COO exercises options and sells 85,163 shares under 10b5-1
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Crinetics Pharmaceuticals Chief Dev. & Operating Officer Jeff E. Knight reported an exercise-and-sale transaction in company stock. On April 8, 2026, he exercised stock options to acquire a total of 78,434 shares of Common Stock at exercise prices of $23.98, $20.02, and $19.64 per share.
On the same date, Knight sold 85,163 shares of Common Stock in open market transactions at a volume weighted average price of $40.10 per share, with individual sale prices ranging from $40.00 to $40.34. The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 105,289 shares of Crinetics common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 85,163 shares ($3,415,036)
Net Sell
7 txns
Insider
Knight Jeff E.
Role
Chief Dev. & Operating Officer
Sold
85,163 shs ($3.42M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 49,474 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 9,624 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 19,336 | $0.00 | -- |
| Exercise | Common Stock | 49,474 | $23.98 | $1.19M |
| Exercise | Common Stock | 9,624 | $20.02 | $193K |
| Exercise | Common Stock | 19,336 | $19.64 | $380K |
| Sale | Common Stock | 85,163 | $40.10 | $3.42M |
Holdings After Transaction:
Stock Option (Right to Buy) — 63,027 shares (Direct);
Common Stock — 161,492 shares (Direct)
Footnotes (1)
- The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $40.10 per share. The range of sale prices on the transaction date was $40.00 to $40.34. Detailed information on the exact number of shares can be obtained from the Issuer upon request. 25% of the shares subject to the option vested on August 30, 2022, and the remaining number of shares subject to the option vested monthly thereafter in thirty-six equal installments. 1/48th of the shares subject to the option vested monthly measured from the vesting commencement date of February 28, 2022. The option is exercisable as follows: 1/48th of the shares subject to the option vest monthly measured from the vesting commencement date of March 1, 2023, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Key Figures
Options exercised: 78,434 shares
Exercise price 1: $23.98 per share
Exercise price 2: $20.02 per share
+5 more
8 metrics
Options exercised
78,434 shares
Total underlying Common Stock acquired via option exercises on April 8, 2026
Exercise price 1
$23.98 per share
Stock Option (Right to Buy) conversion or exercise price
Exercise price 2
$20.02 per share
Stock Option (Right to Buy) conversion or exercise price
Exercise price 3
$19.64 per share
Stock Option (Right to Buy) conversion or exercise price
Shares sold
85,163 shares
Common Stock sold in open market transactions on April 8, 2026
VWAP sale price
$40.10 per share
Volume weighted average sale price for Common Stock sales
Sale price range
$40.00–$40.34 per share
Range of sale prices for the reported Common Stock transactions
Post-transaction holdings
105,289 shares
Common Stock held directly by Knight after the transactions
Key Terms
Rule 10b5-1 trading plan, volume weighted average sale price, Stock Option (Right to Buy), open market transactions, +1 more
5 terms
Rule 10b5-1 trading plan financial
"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
volume weighted average sale price financial
"with a volume weighted average sale price of $40.10 per share"
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
open market transactions financial
"The common stock was sold by the Reporting Person in open market transactions on the transaction date"
Open market transactions are the buying and selling of a company’s shares or other securities conducted on public exchanges or through the wider market rather than through private deals or negotiated placements. They matter to investors because these trades change supply and demand in real time—like shoppers affecting a store’s inventory—and so can move prices, signal management or investor sentiment, affect liquidity, and alter ownership stakes that influence future returns and risk.
Exercise or conversion of derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
FAQ
What did CRNX executive Jeff E. Knight report in this Form 4?
Jeff E. Knight reported exercising stock options and selling shares of Crinetics Pharmaceuticals (CRNX). He exercised options for 78,434 shares and sold 85,163 shares in open market trades, while continuing to hold 105,289 CRNX shares directly.
What stock options did Jeff E. Knight exercise for Crinetics (CRNX)?
Knight exercised three stock option grants covering a total of 78,434 shares of CRNX common stock. The underlying options had exercise prices of $23.98, $20.02, and $19.64 per share, with original expirations in 2031, 2032, and 2033.
What is meant by volume weighted average sale price in this CRNX Form 4?
The volume weighted average sale price of $40.10 reflects the average price across all reported CRNX share sales. Individual trades occurred between $40.00 and $40.34 per share, and the weighted average incorporates each trade’s share volume and price.